CVS Health Corp. has reportedly launched a new prescription drug plan that encourages customers to fill prescriptions at stores that do not sell tobacco products, like CVS. But according to some antitrust experts, the new incentives could raise antitrust concerns.
Reports say the plan charges prescription refill copays of up to $15 more when customers fill prescriptions at a store that sells tobacco products. Those stores include CVS rivals Walgreens, Rite-Aid and others.
While CVS says the new plan was the product of calls for a tobacco-free pharmacy network, experts say there could be legal trouble ahead as the program could unfairly steer customers towards CVS stores.
Former Federal Trade Commission executive David Balto, who is currently an antitrust attorney, says the pharmacy plan is concerning. “There’s no cost savings that comes about from limiting the network,” he said. “it’s really another effort to limit the ability of their rivals to effectively compete.”
The head of the Independent Pharmacy Alliance, John Giampolo, agrees. “It’s an unfair competitive practice,” he said.
Full content: Yahoo Finance
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Kenya’s Competition Authority Proposes Tougher Regulations on Big Tech
May 30, 2024 by
CPI
KKR Secures EU Antitrust Approval for $24 Billion Acquisition of Telecom Italia’s Fixed-Line Network
May 30, 2024 by
CPI
European Court Sides with Tech Giants in Italian Regulatory Dispute
May 30, 2024 by
CPI
US Steel and Nippon Steel Secure International Approvals for $14.9B Merger
May 30, 2024 by
CPI
EU Watchdog Mandates Boardroom Accountability for AI in Banks
May 30, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI